Take a look at some of Monday's midday movers:
Amgen moved higher after a trial showed the pharmaceutical company's new class of cholesterol drug was shown to lower bad cholesterol by as much a 66 percent.
Biogen Idec advanced after the FDA approved the biotech company's hemophilia drug.
Comcast and Time Warner Cable both moved higher following a report that Comcast is considering increasing its current $3-billion buyback by $2.5 billion if its deal to buy Time Warner Cable is approved. Comcast is the parent company of CNBC and CNBC.com.
General Motors fell as questions mounted over why it took so long for the automaker to recall its automobiles with faulty ignition switches. CEO Mary Barra is expected testify on Capital Hill Tuesday.
Johnson & Johnson edged higher after the drugmaker accepted a $4 billion offer from the Carlyle Group to buy the company's Ortho-Clinical Diaganostics business.
Teva Pharmaceuticals rose after the Supreme Court agreed to hear the company's appeal on its top selling multiple sclerosis drug Copaxone. The move could deter generic manufacturers from introducing cheaper versions on the market as soon as May.
Travelers gained ground after Guggenheim upgraded the insurance company's stock to "neutral" from "sell."
Lululmon climbed after Wedbush upgraded the yoga apparel retailer's stock to "outperform" from "neutral."
Blackberry moved lower after Credit Suisse downgraded the smartphone maker's stock to "underperform" from "neutral" and dropped its price target a buck to $6 a share. But Needham upgraded the stock to "hold" from "underperform."
Big Lots rose after KeyBanc upgraded the retailer's stock to "buy" from "hold."
Yelp moved higher after Wells Fargo began coverage of the consumer review website with a "market perform" rating and a price target of $84 to $86 a share.
Energous extended its gains after rising 76 percent in its market debut on Friday. The company is trading under the symbol "WATT."
Biofuel Energy surged in 20 times its normal trading volume after hedge fund manager David Einhorn unveiled a plan to take a controlling stake in the ethanol producer. The stock has a market cap of $31 million.
Curis and Oxygen Biotherapeutics moved higher after the FDA lifted clinical holds on treatments being tested by the companies. Curis has a market cap of $243 million, Oxygen Therapeutics has a market cap of $95 million.
Prana Biotechnology tumbled after the company said its experimental drug to treat Alzheimer's disease failed to meet its main goal in a mid-stage study in patients with a mild form of the condition. Prana has a market cap of $121 million.
—By CNBC's Rich Fisherman.
Questions? Comments? Email us at email@example.com